医药包装

Search documents
重庆正川医药包装材料股份有限公司可转债转股结果暨股份变动公告
Shang Hai Zheng Quan Bao· 2025-10-09 18:46
证券代码:603976 证券简称:正川股份 公告编号:2025-064 债券代码:113624 债券简称:正川转债 重庆正川医药包装材料股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 累计转股情况:截至2025年9月30日,累计共有人民币170,000.00元"正川转债"已转换成公司股票,累 计因转股形成的股份数量为3,652股,占"正川转债"转股前公司已发行股份总额的0.0024%。 ● 未转股可转债情况:截至2025年9月30日,尚未转股的"正川转债"金额为人民币404,830,000.00元, 占"正川转债"发行总额的99.9580%。 ● 本季度转股情况:2025年7月1日至2025年9月30日期间,共有人民币71,000元"正川转债"已转换为公司 股票,因转股形成的股份数量为1,550股。 一、可转债发行上市概况 (二)可转债上市情况 (一)可转债发行情况 经中国证券监督管理委员会证监许可[2021]198号《关于核准重庆正川医药包装材料股份有限公司公开 ...
华兰股份:关于完成工商变更登记并换发营业执照的公告
Zheng Quan Ri Bao· 2025-09-30 09:52
证券日报网讯 9月30日晚间,华兰股份发布公告称,目前,公司已完成工商变更登记及修订后的《公司 章程》备案等手续,并取得了无锡市数据局下发的《登记通知书》以及《营业执照》。 (文章来源:证券日报) ...
重庆正川医药包装材料股份有限公司 关于董事会换届选举的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-09-27 00:47
证券代码:603976 证券简称:正川股份 公告编号:2025-062 债券代码:113624 债券简称:正川转债 重庆正川医药包装材料股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 重庆正川医药包装材料股份有限公司(以下简称"公司")第四届董事会任期即将届满,根据《中华人民 共和国公司法》(以下简称"《公司法》")和《公司章程》等相关规定,公司应按程序进行董事会换届 选举工作。现将本次董事会换届选举情况公告如下: 一、董事会换届选举情况 公司第五届董事会将由9名董事组成,其中非独立董事5名、独立董事3名、 职工代表董事1名。公司于 2025年9月26日召开第四届董事会第二十五次会议,审议通过了《关于董事会换届选举暨提名第五届董 事会非独立董事候选人的议案》及《关于董事会换届选举暨提名第五届董事会独立董事候选人的议 案》。经公司第四届董事会提名委员会资格审查,公司董事会提名邓勇先生、邓秋晗先生、肖清先生、 姜凤安先生、李正德先生为公司第五届董事会非独立董事候选人,提名徐细雄先生、胡文言先 ...
海顺新材:累计回购约587万股
Mei Ri Jing Ji Xin Wen· 2025-09-26 08:56
每经头条(nbdtoutiao)——5年增长33倍,这类新险种卖爆了,身边很多人都需要,30多家险企蜂拥而 入⋯⋯ (记者 曾健辉) 每经AI快讯,海顺新材(SZ 300501,收盘价:17.92元)9月26日晚间发布公告称,截至2025年9月25 日,公司通过深圳证券交易所股票交易系统以集中竞价交易方式回购公司股份累计约587万股,约占公 司总股本的3.03%(以2025年9月19日公司总股本约1.94亿股为基准计算),最高成交价为18.47元/股, 最低成交价为13.5元/股,成交总金额为人民币约9419万元。 2025年1至6月份,海顺新材的营业收入构成为:医药包装新材料占比88.67%,其他占比10.31%,其他 业务占比1.02%。 截至发稿,海顺新材市值为35亿元。 ...
华兰股份股价涨5%,大成基金旗下1只基金重仓,持有62万股浮盈赚取125.86万元
Xin Lang Cai Jing· 2025-09-24 02:49
Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a 5% increase in stock price, reaching 42.63 yuan per share, with a total market capitalization of 7 billion yuan [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%) and conventional rubber stoppers (48.50%) [1] - The company was established on June 4, 1992, and went public on November 1, 2021 [1] Group 2 - According to data, Dachen Fund has a significant holding in Hualan Co., Ltd., with its Dachen Growth Mixed Fund holding 620,000 shares, accounting for 3.29% of the fund's net value [2] - The Dachen Growth Mixed Fund has achieved a year-to-date return of 23.45% and a one-year return of 46.55% [2] - The fund manager, Zou Jian, has been in position for 4 years and 243 days, with the fund's total asset size currently at 1.086 billion yuan [2]
海顺新材:9月18日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-09-19 11:18
每经AI快讯,海顺新材(SZ 300501,收盘价:16.39元)9月19日晚间发布公告称,公司第五届第四十 一次董事会会议于2025年9月18日以通讯会议方式召开。会议审议了《关于调整回购股份价格上限的议 案》等文件。 2025年1至6月份,海顺新材的营业收入构成为:医药包装新材料占比88.67%,其他占比10.31%,其他 业务占比1.02%。 截至发稿,海顺新材市值为32亿元。 每经头条(nbdtoutiao)——5万亿ETF的370名基金经理薪酬大揭秘!他们的日常工作,就是跟着指数 买股票吗? (记者 王晓波) ...
东峰集团:累计回购约1269万股
Sou Hu Cai Jing· 2025-09-10 10:10
Group 1 - Dongfeng Group announced a share repurchase plan, having repurchased approximately 12.69 million shares, accounting for about 0.68% of the total share capital, with a total expenditure of approximately RMB 50.13 million [1] - The highest repurchase price was RMB 4.85 per share, while the lowest was RMB 3.03 per share, exceeding the lower limit of the expected repurchase amount of RMB 50 million [1] - As of the report date, Dongfeng Group's market capitalization stands at RMB 8.9 billion [1] Group 2 - For the first half of 2025, Dongfeng Group's revenue composition is as follows: pharmaceutical packaging 41.31%, membrane new materials 34.19%, paper products 14.47%, other businesses 6.53%, and others 3.06% [1]
力诺药包: 2025年第一次债券持有人会议决议公告
Zheng Quan Zhi Xing· 2025-09-05 16:13
Meeting Overview - The bondholders' meeting of Shandong Linuo Medical Packaging Co., Ltd. was held on September 5, 2025, at 14:00 in the company's conference room [1][2] - One bondholder with voting rights attended the meeting, representing 61,950 bonds, which is 1.53% of the total outstanding bonds of 4,056,337 [1] Voting Results - The proposal was approved with 61,950 bonds in favor, representing a total principal amount of 6,195,000 yuan, which accounted for 100% of the voting rights present [2] - There were no opposing or abstaining votes recorded [2] Legal Opinion - The meeting was witnessed by lawyers from Beijing Zhonglun Law Firm, who confirmed that the meeting's procedures and results complied with relevant laws and regulations, making the resolutions legally binding for all bondholders [2][3]
海顺新材:累计回购约195万股
Mei Ri Jing Ji Xin Wen· 2025-09-01 14:37
Group 1 - The company, Haishun New Materials, announced a share buyback of approximately 1.95 million shares, accounting for 1.01% of its total share capital, with a total transaction amount of approximately 27.23 million RMB [1][1][1] - The highest transaction price during the buyback was 15.12 RMB per share, while the lowest was 13.5 RMB per share [1][1][1] - As of the report date, the market capitalization of Haishun New Materials is 3.2 billion RMB [1][1][1] Group 2 - For the first half of 2025, the revenue composition of Haishun New Materials indicates that pharmaceutical packaging new materials accounted for 88.67% of total revenue, while other segments contributed 10.31% and other businesses 1.02% [1][1][1]
东峰集团:国资入主推动战略转型升级 布局固态电池领域显成效
Zheng Quan Shi Bao Wang· 2025-08-29 09:25
Core Viewpoint - Dongfeng Group reported a significant reduction in net loss for the first half of 2025, indicating substantial improvement in operational quality despite ongoing strategic transformation [1] Financial Performance - The company achieved operating revenue of 604 million yuan in the first half of 2025 [1] - The net loss attributable to shareholders was 61.31 million yuan, a reduction of 52.87% year-on-year, reflecting a notable narrowing of losses [1] Strategic Focus - Dongfeng Group is undergoing a strategic transformation, with a focus on high-tech solid-state and semi-solid battery materials in the new energy sector [1][2] - The company aims to enhance its scale advantages in the Class I pharmaceutical packaging sector to solidify its profit base [1] Business Development - The company’s product portfolio includes new energy separators, PET-based films, PVA high-barrier films, and various pharmaceutical packaging products [1] - Dongfeng Group is actively extending its industrial chain in the new energy battery materials sector, focusing on core materials for semi-solid and solid-state batteries [2] Industry Trends - The Ministry of Industry and Information Technology and local governments have issued multiple policy documents to support the long-term development of solid-state batteries [3] - It is projected that China's solid-state battery shipments will reach 18 GWh by 2027 and 30 GWh by 2028, indicating a significant growth trajectory for the industry [3] Research and Development - The company has achieved several milestones in the new energy materials and solid-state battery fields through partnerships with universities and industry leaders [4] - Collaborations have led to the development of advanced packaging materials and battery components, enhancing the company's competitive edge [4] Corporate Governance - The controlling shareholder of Dongfeng Group has changed to Qizhou Zhishang Enterprise Management Partnership, with the actual controller being the Qizhou State-owned Assets Supervision and Administration Commission [5] - This transition marks the integration of the company's governance system into the state-owned enterprise framework [5] Future Outlook - Under the guidance of Qizhou State-owned Assets, Dongfeng Group will focus on high-end new energy materials and cluster development in pharmaceutical packaging [6] - The company plans to enhance its operational capabilities while optimizing resource allocation in its core business areas [6]